Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
Monday, September 26, 2022Seagen Inc a world leader and pioneer in antibodydrug conjugate ADC therapies and LAVA Therapeutics NV a clinicalstage immunooncology company focused on developing its proprietary Gammabody platform of bispecific gamma delta T cell engagers today ann...
Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor
Wednesday, September 21, 2022Merck a leading science and technology company today announced a collaboration agreement with licensing option with Nerviano Medical Sciences Srl NMS for the nextgeneration highly selective and brainpenetrant PARP poly ADPribose polymerase inhibitor...
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy
Tuesday, September 20, 2022Alterity Therapeutics a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases today announced the approval of its Investigational New Drug IND application by the US Food and Drug Administration FDA...
BioIVT Launches GMP-grade VivoSTART Leukopaks for Cell and Gene Therapy Manufacturing
Tuesday, September 20, 2022BioIVT a leading provider of biospecimens research models and services for drug and diagnostic development today announced the launch of its Good Manufacturing Practice GMP grade VivoSTART leukopaks Leukopaks contain concentrated white blood cells an...
European Commission approves Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss
Monday, September 19, 2022Roche announced that the European Commission EC approved Vabysmo faricimab for the treatment of neovascular or wet agerelated macular degeneration nAMD and visual impairment due to diabetic macular edema DME These retinal conditions are two of the le...
SciSparc Enters Agreement to Acquire Wellution(TM), Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
Wednesday, September 14, 2022SciSparc Ltd a specialty clinicalstage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system today announced the signing of a definitive agreement with Merhavit MRM Holding and Management Ltd...
ProBioGen Receives Employer of the Future and Top Service Awards
Tuesday, September 13, 2022Today the Berlinbased biopharmaceutical company ProBioGen received the Employer of the Future and the Top Service awards at the DIGITAL X event in Cologne Former German Minister for Economics Brigitte Zypries presented the awards in person to ProBio...
AnHeart Therapeutics and NewG Lab Therapeutics Receive Orphan Drug Designation in Korea for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer
Monday, September 12, 2022AnHeart Therapeutics and NewG Lab Therapeutics a subsidiary of NewG Lab Pharma announced that the Ministry of Food and Drug Safety MFDS Republic of Korea has granted the Designation of Orphan Drug ODD to taletrectinib a next generation tyrosine kinas...
Cellusion and Celregen, a member of Fosun Pharma, Enter into Exclusive License Agreement of CLS001 for a Corneal Endothelial Cell Regenerative Therapy in the Greater China Region
Monday, September 12, 2022Cellusion Inc CEO Shin Hatou MD PhD Cellusion a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem with a unique differentiation induction method from iPS cells to Corneal Endothelial Cell Substi...
ProBioGen and City of Hope Announce Commercial License Agreement to Use AGE1.CR.pIX® Vaccine Manufacturing Platform for Cytomegalovirus (CMV) Vaccine
Wednesday, September 07, 2022ProBioGen and City of Hope one of the largest cancer research and treatment organizations in the United States announced today a nonexclusive commercial license agreement that will allow City of Hope to manufacture its innovative synthetic MVAbased C...
